Published on 25/12/2025
Understanding the Impact of Priority Review Vouchers on Rare Disease Drug Approvals
What Is a Priority Review Voucher (PRV)?
The Priority Review Voucher (PRV) is a regulatory incentive offered by the U.S. Food and Drug Administration (FDA) to encourage drug development for underserved populations, particularly in rare and neglected diseases. The PRV allows the sponsor to expedite FDA review of a subsequent new drug application (NDA) or biologics license application (BLA), reducing the review time from the standard 10 months to 6 months.
Initially launched in 2007 for tropical diseases, the program expanded in 2012 to include rare pediatric diseases (RPD), creating a strategic pathway for companies developing treatments for ultra-rare disorders to benefit from accelerated review — or monetize the voucher through sale or licensing.
Eligibility Criteria for a Rare Pediatric Disease PRV
To qualify for a PRV under the Rare Pediatric Disease (RPD) program, the therapeutic candidate must meet specific conditions:
- Designated as Treating a Rare Pediatric Disease: Defined as affecting fewer than 200,000 individuals in the U.S., with onset in childhood
- First-time Approval: The drug must not have previously been approved for the same indication
- Clinically Significant Benefit: Compared to existing therapies, if
Once approved, the sponsor is awarded a PRV that can be used for another product or sold to another company — making it a strategic asset.
How PRVs Accelerate Drug Development
In the world of pharmaceutical innovation, time to market is critical. For rare disease developers, a PRV offers key benefits:
- Shortened FDA Review: From 10 months to 6 months, accelerating launch timelines
- Commercial Edge: First-mover advantage in competitive therapeutic areas
- Valuable Trading Asset: PRVs are transferable and have been sold for up to $350 million
- Investor Appeal: Potential for PRV adds value in fundraising rounds and IPOs
These incentives are especially important for small biotech firms with limited resources who may use PRV sales to fund future trials.
Real-World Example: PRV Monetization
In 2014, BioMarin received a PRV after approval of Vimizim for Morquio A syndrome, a rare pediatric lysosomal storage disorder. The company sold the PRV to Sanofi-Regeneron for $67.5 million to support their product launch and R&D pipeline.
As of 2025, PRV sale prices range from $80 million to $150 million depending on market demand, disease landscape, and potential revenue upside of the accelerated product.
How to Apply for a PRV
The PRV is not automatically granted — sponsors must request it at the time of NDA/BLA submission and include:
- Justification that the condition meets rare pediatric criteria
- Evidence supporting unmet medical need
- Summary of clinical and nonclinical data showing therapeutic benefit
FDA reviews the PRV request alongside the NDA/BLA and includes the decision in the approval letter. PRVs are awarded only upon approval of the application.
Table: PRV vs Traditional Approval Comparison
| Aspect | Traditional Review | With PRV |
|---|---|---|
| Review Time | 10 Months | 6 Months |
| Application Fee | Standard | +$1.2M PRV Usage Fee (2025) |
| Transferable? | No | Yes |
| Market Launch Timing | Delayed | Expedited |
Integration with Other FDA Designations
PRVs can be combined with other FDA expedited programs, enhancing their impact:
- Orphan Drug Designation: 7-year exclusivity and tax credits
- Breakthrough Therapy Designation: Early FDA collaboration and rolling review
- Fast Track: Frequent meetings and priority communications
This strategic stacking of designations provides sponsors with a comprehensive toolkit to bring rare disease therapies to market efficiently.
External Reference
To learn more about rare disease trial registrations and development pathways, visit EU Clinical Trials Register for ongoing studies in rare pediatric populations.
Challenges and Limitations of PRVs
Despite their value, PRVs also come with caveats:
- High Application Fee: A supplemental fee (~$1.2 million in 2025) is charged when redeeming a PRV
- Regulatory Uncertainty: The PRV program has faced periodic legislative sunset clauses
- Market Speculation: PRV value can fluctuate based on buyer availability
- No Guarantee of Approval: FDA still reviews application rigorously despite priority review
Sponsors must carefully weigh these risks when incorporating PRVs into development strategy.
Future of PRVs in Rare Disease Policy
As of 2025, the PRV program remains active through congressional renewal, with growing calls to expand eligibility to ultra-rare adult-onset diseases. Stakeholders also propose new oversight mechanisms to ensure that approved therapies offer meaningful benefit and that PRVs are not misused for commercial gain alone.
Industry groups, patient advocacy organizations, and policy makers continue to debate the best way to balance PRV incentives with regulatory rigor and public health needs.
Conclusion: Turning Rare Disease Innovation into Market Success
Priority Review Vouchers have emerged as a powerful driver of innovation in rare and pediatric disease treatment. They not only accelerate access for patients but also enable financial sustainability for sponsors, especially smaller biotech companies.
By understanding the eligibility requirements, market dynamics, and strategic implications of PRVs, developers can effectively integrate them into regulatory planning — transforming rare disease breakthroughs into real-world impact.